Indiplon
Indiplon[edit | edit source]
Indiplon is a nonbenzodiazepine hypnotic agent that was developed for the treatment of insomnia. It acts as a positive allosteric modulator of the GABA_A receptor, which is a type of neurotransmitter receptor in the central nervous system.
Mechanism of Action[edit | edit source]
Indiplon works by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor. This receptor is a ligand-gated ion channel that, when activated, allows chloride ions to enter the neuron, leading to hyperpolarization and decreased neuronal excitability. By modulating this receptor, Indiplon increases the inhibitory effects of GABA, promoting sedation and sleep.
Pharmacokinetics[edit | edit source]
Indiplon is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It is extensively metabolized in the liver by the cytochrome P450 enzyme system, primarily by CYP3A4. The metabolites are excreted in the urine. The half-life of Indiplon is approximately 1 to 2 hours, which makes it suitable for use as a sleep aid with minimal hangover effect the next day.
Clinical Use[edit | edit source]
Indiplon was developed to treat insomnia, particularly difficulties with sleep onset. It was designed to have a rapid onset of action and a short duration, making it effective for individuals who have trouble falling asleep but do not necessarily have issues with staying asleep.
Development and Approval[edit | edit source]
Indiplon was developed by Neurocrine Biosciences and was submitted for approval to the United States Food and Drug Administration (FDA). However, the FDA issued a non-approval letter, citing concerns about the drug's safety and efficacy profile. As a result, Indiplon was never marketed in the United States.
Side Effects[edit | edit source]
Common side effects of Indiplon include drowsiness, dizziness, and headache. Like other hypnotics, it may also cause amnesia, confusion, and impaired coordination. There is also a potential for dependence and withdrawal symptoms with prolonged use.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
